New transplant approach could help more patients with blood disorders
NCT ID NCT05736419
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a stem cell transplant from half-matched (haploidentical) donors for people with sickle cell disease or beta-thalassemia. Before the transplant, patients receive drugs to lower their immune system, which may reduce the risk of serious side effects like graft failure or graft-versus-host disease. The trial aims to enroll 24 adults and children aged 2 to 50. If it works, this could provide a treatment option for those without a fully matched donor.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fludarabine, cyclophosphamide, tacrolimus, mycophenolate mofetil, rabbit ATG, dexamethasone
What this could lead to
If successful, this approach could offer a safer stem cell transplant option for people with sickle cell disease or thalassemia who lack a fully matched donor, potentially controlling the disease long-term.
What could go wrong
This is a small, early-phase trial with only 24 participants. The treatment involves strong immune-suppressing drugs, which carry risks of infection, graft failure, or graft-versus-host disease. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Memorial Sloan Kettering Bergen (Consent only)
RECRUITINGMontvale, New Jersey, 07645, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Monmouth (Consent only)
RECRUITINGMiddletown, New Jersey, 07748, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Nassau (All protocol activities)
RECRUITINGRockville Centre, New York, 11553, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Suffolk - Commack (Consent only)
RECRUITINGCommack, New York, 11725, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Westchester (Consent only)
RECRUITINGHarrison, New York, 10604, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering at Basking Ridge (Consent only)
RECRUITINGBasking Ridge, New Jersey, 07920, United States
Contact Phone: •••-•••-••••